BACKGROUND: The aim of this study was to compare the outcomes of the management of perianal fistulas in Crohn disease between infliximab, surgery or a combination of surgery and infliximab. METHODS: We prospectively subdivided 35 consecutive patients with Crohn disease with complex perianal fistulas into 3 groups: 11 patients received infliximab (5 mg/kg intravenously at 0, 2 and 6 wk; group A), 10 underwent surgery (group B) and 14 received a combination of surgery and postoperative infliximab (group C). We evaluated the rate and time of healing of perianal fistulas, the rate of recurrences and time to relapse at a median follow-up of 18.8 (standard deviation [SD] 10.8, range 8-38) months. RESULTS: The time to healing of fistulas was significantly shorter among patients who received surgery and infliximab than among those who received surgery alone (p < 0.05) and was close to statistically shorter among those who received both treatments than among those who received infliximab alone (p = 0.06). Patients who received surgery and infliximab had a significantly longer mean time to relapse (p < 0.05) than those who received infliximab (mean 2.6 [SD 0.7] mo) or surgery alone (mean 3.6 [SD 0.5] mo). CONCLUSION: We found better outcomes among patients who received a combination of surgery and infliximab therapy. These patients experienced a short time to healing of fistulas and significantly longer mean time to relapse of complex fistulas.
BACKGROUND: The aim of this study was to compare the outcomes of the management of perianal fistulas in Crohn disease between infliximab, surgery or a combination of surgery and infliximab. METHODS: We prospectively subdivided 35 consecutive patients with Crohn disease with complex perianal fistulas into 3 groups: 11 patients received infliximab (5 mg/kg intravenously at 0, 2 and 6 wk; group A), 10 underwent surgery (group B) and 14 received a combination of surgery and postoperative infliximab (group C). We evaluated the rate and time of healing of perianal fistulas, the rate of recurrences and time to relapse at a median follow-up of 18.8 (standard deviation [SD] 10.8, range 8-38) months. RESULTS: The time to healing of fistulas was significantly shorter among patients who received surgery and infliximab than among those who received surgery alone (p < 0.05) and was close to statistically shorter among those who received both treatments than among those who received infliximab alone (p = 0.06). Patients who received surgery and infliximab had a significantly longer mean time to relapse (p < 0.05) than those who received infliximab (mean 2.6 [SD 0.7] mo) or surgery alone (mean 3.6 [SD 0.5] mo). CONCLUSION: We found better outcomes among patients who received a combination of surgery and infliximab therapy. These patients experienced a short time to healing of fistulas and significantly longer mean time to relapse of complex fistulas.
Authors: David A Schwartz; Edward V Loftus; William J Tremaine; Remo Panaccione; W Scott Harmsen; Alan R Zinsmeister; William J Sandborn Journal: Gastroenterology Date: 2002-04 Impact factor: 22.682
Authors: Dawnelle R Topstad; Remo Panaccione; John A Heine; Douglas R E Johnson; Anthony R MacLean; W Donald Buie Journal: Dis Colon Rectum Date: 2003-05 Impact factor: 4.585
Authors: Clifford Sample; Robert J Bailey; Dennis Todoruk; Daniel Sadowski; Leah Gramlich; Mario Milan; Raeleen Cherry; Mang Ma; Eoin Lalor; John McKaigney; Richard Sherbaniuk; Kata Matic; Connie Switzer; Richard N Fedorak Journal: Can J Gastroenterol Date: 2002-03 Impact factor: 3.522
Authors: Wolfgang B Gaertner; Alejandra Decanini; Anders Mellgren; Ann C Lowry; Stanley M Goldberg; Robert D Madoff; Michael P Spencer Journal: Dis Colon Rectum Date: 2007-09-27 Impact factor: 4.585
Authors: Yong Beom Cho; Kyu Joo Park; Sang Nam Yoon; Kee Ho Song; Do Sun Kim; Sang Hun Jung; Mihyung Kim; Hee Young Jeong; Chang Sik Yu Journal: Stem Cells Transl Med Date: 2015-03-31 Impact factor: 6.940
Authors: G Pellino; D S Keller; G M Sampietro; I Angriman; M Carvello; V Celentano; F Colombo; F Di Candido; S Laureti; G Luglio; G Poggioli; M Rottoli; S Scaringi; G Sciaudone; G Sica; L Sofo; S Leone; S Danese; A Spinelli; G Delaini; F Selvaggi Journal: Tech Coloproctol Date: 2020-03-14 Impact factor: 3.781